Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

Curigliano G., Shapiro GI., Kristeleit RS., Abdul Razak AR., Leong S., Alsina M., Giordano A., Gelmon KA., Stringer-Reasor E., Vaishampayan UN., Middleton M., Olszanski AJ., Rugo HS., Kern KA., Pathan N., Perea R., Pierce KJ., Mutka SC., Wainberg ZA.

DOI

10.1038/s41416-023-02161-w

Type

Journal article

Journal

Br J Cancer

Publication Date

01/2023

Volume

128

Permalink Original publication